Online Event: Synthetic Biology and National Security: Risks and Opportunities (PART 1 of 2)
Please join us on Tuesday, April 14th for the first of a two-part online discussion about synthetic biology’s implications for national security.
The Center for Strategic and International Studies (CSIS) invites you to attend the second event in our Synthetic Biology: The Ongoing Technology Revolution Series. This two-part online event will focus on synthetic biology’s implications for national security. Our discussion will explore how synthetic biology is shaping the fields of biosecurity and biodefense. We will also consider how the national security community can manage the risks and opportunities associated with this important, dual-use technology.
Synthetic Biology: The Ongoing Technology Revolution Series
Emerging technologies—such as artificial intelligence, quantum computing, 5G, and synthetic biology—drive security and economic competition and are increasingly shaping national strategies. To develop an effective strategy for synthetic biology, policy makers and the general public need a better understanding of synthetic biology’s underlying capabilities, state of development, and diverse applications. Through a series of four symposia, CSIS will explore synthetic biology’s wide-ranging applications—from advanced microelectronics and materials to nutrition and cosmetics —and opportunities to shape its future development in support of U.S. security and economic interests. This series will include targeted discussions on synthetic biology’s:
- Present and future potential as a critical emerging technology;
- Economic and societal implications;
- National security opportunities and risks; and
- Implications for emerging technology policy.
CSIS hopes you will join the first event in our two-part online discussion about synthetic biology and national security, hosted on April 14th. Please stay tuned for the second part of our discussion on April 21st and watch past events online.
This series of events is sponsored by Ginkgo Bioworks, Inc.